Global pharmaceutical supply chains are becoming increasingly dependent on China and India, with the two countries playing a central role in the production of active pharmaceutical ingredients (APIs), generic medicines and other critical pharmaceutical inputs.
China remains a major supplier of APIs and chemical intermediates used to manufacture medicines worldwide, while India has established itself as one of the leading producers and exporters of generic drugs. Their expanding roles have made both countries critical links in the global pharmaceutical supply chain.
India’s pharmaceutical industry has a particularly strong position in generic medicines, supplying products to markets across North America, Europe, Africa and other regions. Indian manufacturers also rely on China for a significant share of certain APIs and intermediates, creating an important two-way supply-chain relationship.
The concentration of production in the two countries has helped pharmaceutical companies access competitive manufacturing costs and large-scale production capacity. However, it has also raised concerns about supply-chain resilience, particularly when geopolitical tensions, trade restrictions, transportation disruptions or production outages affect international flows.
Governments and pharmaceutical companies in several markets are therefore seeking to diversify sourcing and increase domestic manufacturing of strategically important medicines and pharmaceutical ingredients. Building alternative production capacity, however, can take considerable time and may involve higher costs.
For India, the growing importance of its pharmaceutical sector presents both opportunities and challenges. Rising global demand for generic medicines and contract manufacturing could support further export growth, while reducing dependence on imported APIs remains an important objective for the domestic industry.
China’s continued dominance in upstream chemical and API production means that supply disruptions there can have consequences for manufacturers in India and other pharmaceutical markets. Companies are consequently increasing efforts to maintain inventories, diversify suppliers and strengthen supply-chain visibility.
The evolving structure of the global pharmaceutical industry is likely to keep China and India at the centre of international medicine supply chains. At the same time, the push for greater resilience could encourage investment in manufacturing capacity across other regions, gradually creating a more diversified global pharmaceutical network.